BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MDY Healthcare Preliminary Results


3/8/2011 9:41:08 AM

8 March 2011: MDY Healthcare plc (“MDY Healthcare” or the “Company”), the strategic investor in healthcare companies, today announces its preliminary results for the reporting period ended 30 September 2010.

Financial Highlights

- Total investments valued at £7.31 million (30 September 2009: £9.43 million) with cash and cash equivalents of £0.28 million (30 September 2009: £1.13 million).

- Consolidated net asset value per share as at 30 September 2010 of 35p (30 September 2009: 58p).

- Net loss after tax for reporting period £3.63 million (2009: £1.73 million).

- Valuation of strategic private investments, Medivance and Stanmore, maintained at cost, representing the fair value of the relevant investment, although both have performed well.

- After end of reporting period, cash position strengthened by issuing new shares in placing to a major shareholder and by selling part of the Company’s shareholding in Stanmore, raising £150,000 and £600,000 respectively.

Portfolio Highlights

- Following strategic review, primary focus to be on investments in Medivance and Stanmore.

- Medivance continues to make excellent progress, achieving quarter on quarter revenue growth and is well placed to deliver value for shareholders.

- Medivance had worldwide consolidated revenues of US$29 million (unaudited) in the year ended 31 December 2010.

- Stanmore achieved revenues of approximately £6.1 million (unaudited) for 12 months ended 31 December 2010 (2009: £5.6 million (audited)). Key Transfemoral ITAP trial continues at the Royal National Orthopaedic Hospital in Stanmore.

- Review of investments in AOI and Trust William leading to prudent write-down of valuations and commencement of strategic review for Trust William.

Grahame Cook, Chairman, said:

“During the year we restructured the business and made progress in reducing our overheads and extending our cash runway. We divested our portfolio of quoted stocks and tightened our focus on our main strategic private investments, Medivance and Stanmore, both of which have continued to make excellent progress in their respective markets.”

For further information, please contact:

MDY Healthcare plc Grahame Cook, Chairman +44 (0) 207 647 1800 grahame.cook@MDYhealthcare.com

Financial Dynamics Ben Atwell, Susan Quigley +44 (0) 207 831 3113 ben.atwell@fd.com, susan.quigley@fd.com

Brewin Dolphin Limited (Nomad) Matt Davis +44 (0) 845 270 8600

About MDY Healthcare

MDY Healthcare plc is a sector specialised strategic investing company quoted on AIM (ticker symbol: MDY). The Company seeks to achieve superior returns for shareholders by investing globally in companies across the healthcare sector. The directors and executive have significant operational and investment experience in the sector and therefore the ability to identify and review a wide range of potential investments.

Further information can be found on the website www.mdyhealthcare.com.

Mo Noonan Senior Manager Financial Dynamics Holborn Gate, 26 Southampton Buildings London, WC2A 1PB D +44 (0)20 7269 7116 M +44 (0)7876 444 977 www.fd.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES